Clinical Features and Lymphocyte Subsets in Recovered Covid-19 Patients With Prolonged Viral RNA Shedding Duration

Wei-yun Zhang  
First Affiliated Hospital of Soochow University  https://orcid.org/0000-0003-1413-6518

Kai Wu  
First Affiliated Hospital of Soochow University

Ying-ying Liu  
First Affiliated Hospital of Soochow University

Chang-guo Wang  
First Affiliated Hospital of Soochow University

Jian-an Huang  
First Affiliated Hospital of Soochow University

Jun-hong Jiang  
First Affiliated Hospital of Soochow University

Da-xiong Zeng  (zengdaxiong@suda.edu.cn)

Case Report

Keywords: COVID-19, viral RNA, shedding duration, SARS-CoV-2, immunologic dysfunction

Posted Date: June 8th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-33073/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published at American Journal of Therapeutics on May 28th, 2021. See the published version at https://doi.org/10.1097/MJT.0000000000001293.
Abstract

Background: The 2019 novel coronavirus disease (COVID-19) spread in many countries. Data about viral shedding duration, particularly the prolonged ones of the pathogen SARS-Coronavirus-2 (SARS-CoV-2) is scarce. The longest viral RNA shedding duration reported previously was 37 days. Herein, we report the clinical and immunologic features of recovered COVID-19 cases with a medium viral RNA shedding duration of 44 days.

Cases presentation: Nine laboratory-confirmed COVID-19 cases from Wuhan with viral RNA shedding duration more than 30 days were included in our study. Of them were moderate. Although inflammatory markers were significantly higher, the medium duration in severe patients was similar to that in moderate patients (44.5 days vs. 43.6 days). Severe patients showed higher NK cells levels, although the T cells and B cells were lower as compared with moderate patients. Contrary to previous reports in influenza, prolonged viral shedding time did not cause poor prognosis in this study.

Conclusions: There could be characteristic immunological dysfunction in COVID-19 patients with prolonged viral shedding duration and interestingly, prolonged viral shedding duration seemed not to be related with poor prognosis.

Background

SARS-Coronavirus-2 (SARS-CoV-2) is the focus of global attention which attributed to an outbreak of a severe respiratory illness since December 2019 in Wuhan, China. This severe respiratory illness originated in Wuhan City in the Hubei province in China and is capable of rapid community transmission (1).

The level and duration of SARS-CoV-2 virus replication are important factors in assessing the risk of transmission and guiding decisions regarding isolation of patients. A previous study reported that the median duration of viral shedding was 20 days in survivors (2). The longest duration of viral shedding was 37 days in survivors. It has been reported in seasonal or pandemic influenza viral shedding duration that the longer duration of viral RNA shedding was correlated with worse patient prognosis (3–4). It remains unclear whether the SARS-CoV-2 RNA shedding duration affected progression of COVID-19 or not. Here, we report the clinical and immunologic features of a series of COVID-19 cases with prolonged viral RNA shedding duration (the median duration was 44 days).

Cases Presentation

Methods and Patients

This retrospective study enrolled 9 laboratory-confirmed COVID-19 adult inpatients admitted to Wuhan Tongji Hospital from February 09 to March 09, 2020. Diagnosis and clinical classification of COVID-19 were according to the Chinese management guideline for COVID-19 (version 7.0) and the World Health Organization interim guidance. Severe and critically ill COVID-19 patients were identified by reviewing and analyzing admission logs and histories of all available electronic medical records and patient care resources by two physicians. This study was approved by the institutional review boards at Wuhan Tongji Hospital and the First Affiliated Hospital of Soochow University. As an emerging infectious disease, written informed consent was exempted.

Data Collection

Demographic characteristics (age and gender), clinical features (comorbidities, laboratory findings, diseases severity, treatments and outcomes) were recorded. Patients were followed-up from admission to persistent negative detection of pharyngeal swabs specimens. The SARS-CoV-2 RNA shedding duration was defined as the interval between illness onset and the date of the last pharyngeal swab with a positive finding. Patients were followed-up from admission to 28 days in hospital, hospital discharge, or death, whichever came first.

Statistical analysis

Continuous data with normal distribution were presented as mean ± standard deviation. Frequency data were expressed as proportions. Data were analyzed using SPSS 25.0.

Results

Total of 9 adult COVID-19 inpatients were included. The median age was 64.3 years old (34–87 yrs). 6 cases were male. The most popular comorbidity was hypertension (5/9). The most common symptoms were fever (6/9) and cough (5/9). All patients were survived at 28-days after admission, with 5 cases discharged. 2 patients were improved in hospital and 2 patients remained receiving invasive machinery ventilation (IMV) and continuous renal replacement therapy (CRRT).

For all patients, the median viral RNA shedding duration was 44 days (30–62 days). The median viral RNA shedding duration in severe or critical patients was similar to that in moderate patients (44.5 days vs. 43.6 days). The severe and critical patients were older, have a lower lymphocyte count \((O.58 \times 10^9 /L \text{ vs. } 1.72 \times 10^9 /L)\) and ALB levels \((29.75 \text{ g/L vs. } 40.06 \text{ g/L})\), a higher levels of hs-CRP \((89.33 \text{ mg/L vs. } 2.56 \text{ mg/L})\), interleukin 6 \((35.62 \text{ pg/ml vs. } 2.27 \text{ pg/ml})\), d-dimer \((1.67 \text{ µg/ml vs. } 0.36 \text{ µg/ml})\), cTnI \((91.03 \text{ pg/ml vs. } 2.10 \text{ pg/ml})\), and lactate dehydrogenase \((402.25 \text{ U/L vs. } 182.40 \text{ U/L})\). The 2019 novel coronavirus disease (COVID-19) spread in many countries. Data about viral shedding duration, particularly the prolonged ones of the pathogen SARS-Coronavirus-2 (SARS-CoV-2) is scarce. The longest viral RNA shedding duration reported previously was 37 days. Herein, we report the clinical and immunologic features of recovered COVID-19 cases with a medium viral RNA shedding duration of 44 days.

We also detected the lymphocyte subsets levels in peripheral blood samples. As compared with moderate COVID-19 cases, the severe and critical patients showed a lower levels of CD3^+CD19^- T cells \((675.75 \text{ N/µl vs. } 1370.40 \text{ N/µl})\), CD3^+CD19^- T cells \((130.25 \text{ N/µl vs. } 275.00 \text{ N/µl})\), CD3^+CD4^- Treg \((380.25 \text{ N/µl vs. } 734.80 \text{ N/µl})\) and CD3^+CD8^- Ts cells \((283.50 \text{ N/µl vs. } 561.40 \text{ N/µl})\). Interestingly, severe and critical patients have a higher levels of CD3^+CD16^CD56^ NK
cells (318.25 N/µl vs. 232.20 N/µl). All patients showed bilateral lung lesion in CT findings (patchy shadowing or ground-glass opacity), 2 patients showed pleural effusion.

**Discussion**

Our study focused on the clinical features and immunologic manifestations of COVID-19 patients with prolonged viral RNA shedding duration. Duration of infectious virus replication are crucial factors in evaluating the transmission risk (1). The median shedding duration was 44 days, which was far longer than that reported in previous study (2). In this study, the longest viral RNA shedding duration was 62 days. It might be the longest viral shedding duration of COVID-19 to date. The difference might be due to the epidemiological feature of patients enrolled, which were enrolled form the designated hospital for COVID-19 patients of severe or critical illness in Wuhan, the most serious epidemic region in China. Delayed hospital admission was associated with prolonged viral shedding duration, as they received insufficient treatment when outside of hospital. We need more data to determine transmission dynamics and inform our screening practices (5).

Previous reports about influenza A (H7N9) and respiratory syncytial virus revealed that prolonged viral shedding duration associated with risk of complications and poor prognosis (3–4). Contrarily, all patients in our study remain survived although their viral RNA shedding duration exceeded 30 days. It indicated that prolonged viral RNA shedding was not always associated with poor prognosis. This might indicate the specificity of SARS-CoV-2. The stabilizing mutation falling in the nsp2 protein could account for COVID-2019 high ability of contagious, while the destabilizing mutation in nsp3 proteins could suggest a potential mechanism differentiating COVID-2019 from SARS (6–7). The molecular divergence of SARS-CoV-2 evolved into two major types with different characteristics (7). Furthermore, the diversity of mortality in different region of China might be due to the virological dynamics and epidemiological characteristics (8).

Although the inflammatory markers were obviously different (such as hs-CRP and interleukin 6) between severe patients and common patients, the median duration of viral RNA shedding was similar. We did not find this relationship between viral shedding and disease severity. The balance between viral load and immune system was one of the most important factors determined diseases progression or not. SARS-CoV-2 infection can activate innate and adaptive immune responses (9). However, uncontrolled inflammatory innate responses and impaired adaptive immune responses contributed to both locally and systemically harmful tissue damage. Although the severe and critical patients showed obvious lymphocytopenia and dysregulation of lymphocytes subsets, their NK cells levels were higher than common patents. This might be helpful for immune responses against SARS-CoV-2 infection. The differentiation of naive CD4+ T-cells into effector and memory subsets is one of the most fundamental facets of T-cell-mediated immunity (10). Additionally, the antivirus treatment might affect the disease progression.
Table 1
The clinical and immunologic characteristics of all patients.

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5</th>
<th>Case 6</th>
<th>Case 7</th>
<th>Case 8</th>
<th>Case 9</th>
<th>Average (severe+critical)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>81</td>
<td>81</td>
<td>87</td>
<td>55</td>
<td>49</td>
<td>72</td>
<td>34</td>
<td>66</td>
<td>54</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>CHD, HPT</td>
<td>DM</td>
<td>COPD, HPT</td>
<td>DM, HP</td>
<td>–</td>
<td>–</td>
<td>HPU</td>
<td>–</td>
<td>DM, HPT</td>
</tr>
<tr>
<td>Severity</td>
<td>Critical</td>
<td>Critical</td>
<td>Severe</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Severe</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
</tr>
<tr>
<td>First symptom</td>
<td>Fever</td>
<td>Cough</td>
<td>Cough</td>
<td>Dyspnea</td>
<td>Fever</td>
<td>Cough</td>
<td>Fatigue</td>
<td>Myalgia</td>
<td>Cough</td>
</tr>
<tr>
<td>Lab findings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WBC (10⁹ /L)</td>
<td>4.00</td>
<td>8.66</td>
<td>6.08</td>
<td>7.07</td>
<td>3.64</td>
<td>7.48</td>
<td>7.99</td>
<td>4.93</td>
<td>5.13</td>
</tr>
<tr>
<td>Lym (10⁹ /L)</td>
<td>0.49</td>
<td>0.35</td>
<td>0.75</td>
<td>1.72</td>
<td>1.5</td>
<td>0.72</td>
<td>1.91</td>
<td>1.84</td>
<td>1.62</td>
</tr>
<tr>
<td>Platelet (10⁹ /L)</td>
<td>398</td>
<td>213</td>
<td>174</td>
<td>266</td>
<td>255</td>
<td>268</td>
<td>144</td>
<td>188</td>
<td>145</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>30.40</td>
<td>27.50</td>
<td>34.10</td>
<td>33.40</td>
<td>38.50</td>
<td>27.00</td>
<td>44.90</td>
<td>40.10</td>
<td>29.75</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>11</td>
<td>72</td>
<td>10</td>
<td>7</td>
<td>27</td>
<td>299</td>
<td>113</td>
<td>21</td>
<td>47</td>
</tr>
<tr>
<td>Cretinine (μM)</td>
<td>96</td>
<td>149</td>
<td>100</td>
<td>44</td>
<td>67</td>
<td>66</td>
<td>86</td>
<td>59</td>
<td>43</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>247</td>
<td>720</td>
<td>344</td>
<td>280</td>
<td>167</td>
<td>298</td>
<td>166</td>
<td>150</td>
<td>149</td>
</tr>
<tr>
<td>hs-tcTNI (pg/ml)</td>
<td>7.4</td>
<td>24.6</td>
<td>322</td>
<td>2.8</td>
<td>1.9</td>
<td>10.1</td>
<td>1.9</td>
<td>2</td>
<td>1.9</td>
</tr>
<tr>
<td>D-dimer (μg/ml)</td>
<td>0.56</td>
<td>2.04</td>
<td>1.81</td>
<td>0.82</td>
<td>0.22</td>
<td>2.27</td>
<td>0.22</td>
<td>0.25</td>
<td>0.28</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>81.9</td>
<td>147.5</td>
<td>56.4</td>
<td>44</td>
<td>67</td>
<td>66</td>
<td>86</td>
<td>59</td>
<td>43</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>16.19</td>
<td>54.08</td>
<td>25.25</td>
<td>1.61</td>
<td>2.83</td>
<td>46.96</td>
<td>1.5</td>
<td>2.1</td>
<td>3.3</td>
</tr>
<tr>
<td>PCT (ng/ml)</td>
<td>0.1</td>
<td>0.35</td>
<td>0.08</td>
<td>0.06</td>
<td>0.06</td>
<td>0.09</td>
<td>0.09</td>
<td>0.05</td>
<td>0.07</td>
</tr>
<tr>
<td>Lymphocyte subsets in peripheral blood (number/μl)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD3⁺CD19⁺T cells</td>
<td>347</td>
<td>410</td>
<td>771</td>
<td>1508</td>
<td>1119</td>
<td>1175</td>
<td>1608</td>
<td>1290</td>
<td>1327</td>
</tr>
<tr>
<td>CD3⁺CD19⁺B cells</td>
<td>101</td>
<td>291</td>
<td>18</td>
<td>292</td>
<td>263</td>
<td>111</td>
<td>224</td>
<td>389</td>
<td>207</td>
</tr>
<tr>
<td>CD3⁺CD4⁺Treg</td>
<td>278</td>
<td>281</td>
<td>389</td>
<td>846</td>
<td>745</td>
<td>573</td>
<td>573</td>
<td>1020</td>
<td>490</td>
</tr>
<tr>
<td>CD3⁺CD8⁺Ts</td>
<td>65</td>
<td>117</td>
<td>358</td>
<td>573</td>
<td>349</td>
<td>594</td>
<td>304</td>
<td>205</td>
<td>329</td>
</tr>
<tr>
<td>CD3⁺CD16⁺CD56⁺NK cells</td>
<td>97</td>
<td>127</td>
<td>167</td>
<td>87</td>
<td>236</td>
<td>882</td>
<td>304</td>
<td>205</td>
<td>329</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Antibiotics</th>
<th>Moxi</th>
<th>Merop</th>
<th>Cefop</th>
<th>Moxi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antivirus</td>
<td>Lopi, Arbi</td>
<td>Lopi</td>
<td>Arbi</td>
<td>Arbi</td>
<td>Lopi, Arbi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CT findings</th>
<th>Bilateral patchy shadowing</th>
<th>+</th>
<th>+</th>
<th>+</th>
<th>+</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilateral GGO</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>28-days outcomes</td>
<td>IMV</td>
<td>IMV</td>
<td>Improved</td>
<td>Discharged</td>
<td>Discharged</td>
<td>Discharged</td>
</tr>
<tr>
<td>Virus shedding duration (d)</td>
<td>43</td>
<td>30</td>
<td>43</td>
<td>49</td>
<td>41</td>
<td>62</td>
</tr>
</tbody>
</table>

**Abbreviation**: CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; HPT: hypertension; HPU: hyperuricemia; DM: diabetes mellitus; Lym: ritonavir; Arbi: Arbidol; PCT: procalsitonin; IMV: invasive machinery ventilation; CRRT: continuous renal replacement therapy; Moxi: moxifloxacin; Merop: meropenem; GGO: ground-glass opacity.
**Conclusion**

In conclusion, our study focuses on the clinical and immunologic features in COVID-19 patients with prolonged viral RNA shedding duration. Severe COVID-19 patients have a lower level of CD3⁺CD19⁻ T cells and CD3⁺CD19⁺ B cells but a higher CD3⁺CD16⁺CD56⁺ NK cells levels. Contrary to previous reports in influenza, prolonged viral shedding time did not cause poor prognosis in this study. However, further studies are needed to determine the virological dynamics.

**Abbreviations**

COVID-19
The 2019 novel coronavirus disease; SARS-CoV-2:SARS-Coronavirus-2; IMV: invasive machinery ventilation; CRRT: continuous renal replacement therapy; hs-CRP: high-sensitivity C-reactive protein; RNA: Ribonucleic Acid; NK cells: natural killer cells; CD: Cluster of Differentiation; Treg: Regulatory T cells; Ts cells: suppressor T cells; CT: Computed Tomography; cTnI: cardiac troponin I.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Written informed consent for publication of the clinical details and clinical images was obtained from the patient.

**Availability of data and materials**
Not applicable.

**Competing interests:**
The authors declare that they have no competing interests.

**Funding**
This work was supported by Program of Key Talents of Medical Science in Jiangsu Province (QNRC2016745), Suzhou science and technology development plan (SYS202008), Clinical Medicine Center of Suzhou (No.SZZX201502) and Suzhou Key Laboratory for Respiratory Medicine (No. SZS201617).

**Author’s contributions**

WYZ, KW participated in the collection and check of electronic medical records and patient care resources. YYL analysed the data with the assistance from CGW. DXZ wrote the first draft, JAH and JHJ edited the final draft. All authors had read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**Author details**

1 Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Soochow University.

**References**

1. 10.1016/S0140-6736(20)30744-3


7. 10.1002/jmv.25719.

8. 10.1183/13993003.00562-2020


12. 10.1183/13993003.00562-2020


Figures